These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 35105887)

  • 1. The DNA methylome of cervical cells can predict the presence of ovarian cancer.
    Barrett JE; Jones A; Evans I; Reisel D; Herzog C; Chindera K; Kristiansen M; Leavy OC; Manchanda R; Bjørge L; Zikan M; Cibula D; Widschwendter M
    Nat Commun; 2022 Feb; 13(1):448. PubMed ID: 35105887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic reprogramming of fallopian tube fimbriae in BRCA mutation carriers defines early ovarian cancer evolution.
    Bartlett TE; Chindera K; McDermott J; Breeze CE; Cooke WR; Jones A; Reisel D; Karegodar ST; Arora R; Beck S; Menon U; Dubeau L; Widschwendter M
    Nat Commun; 2016 May; 7():11620. PubMed ID: 27216078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation.
    Kotsopoulos J; Gronwald J; Karlan B; Rosen B; Huzarski T; Moller P; Lynch HT; Singer CF; Senter L; Neuhausen SL; Tung N; Eisen A; Foulkes WD; Ainsworth P; Sun P; Lubinski J; Narod SA;
    Gynecol Oncol; 2018 Jul; 150(1):85-91. PubMed ID: 29793803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers.
    Staff S; Tolonen T; Laasanen SL; Mecklin JP; Isola J; Mäenpää J
    Int J Gynecol Pathol; 2014 May; 33(3):309-16. PubMed ID: 24681744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence, spectrum, and founder effect of BRCA1 and BRCA2 mutations in epithelial ovarian cancer from the Middle East.
    Siraj AK; Bu R; Iqbal K; Siraj N; Al-Haqawi W; Al-Badawi IA; Parvathareddy SK; Masoodi T; Tulbah A; Al-Dayel F; Al-Kuraya KS
    Hum Mutat; 2019 Jun; 40(6):729-733. PubMed ID: 30825404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The WID-BC-index identifies women with primary poor prognostic breast cancer based on DNA methylation in cervical samples.
    Barrett JE; Herzog C; Jones A; Leavy OC; Evans I; Knapp S; Reisel D; Nazarenko T; Kim YN; Franchi D; Ryan A; Franks J; Bjørge L; Zikan M; Cibula D; Harbeck N; Colombo N; Dudbridge F; Jones L; Sundström K; Dillner J; Rådestad AF; Gemzell-Danielsson K; Pashayan N; Widschwendter M
    Nat Commun; 2022 Feb; 13(1):449. PubMed ID: 35105882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma.
    Soslow RA; Han G; Park KJ; Garg K; Olvera N; Spriggs DR; Kauff ND; Levine DA
    Mod Pathol; 2012 Apr; 25(4):625-36. PubMed ID: 22193042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers.
    Maxwell KN; Wubbenhorst B; Wenz BM; De Sloover D; Pluta J; Emery L; Barrett A; Kraya AA; Anastopoulos IN; Yu S; Jiang Y; Chen H; Zhang NR; Hackman N; D'Andrea K; Daber R; Morrissette JJD; Mitra N; Feldman M; Domchek SM; Nathanson KL
    Nat Commun; 2017 Aug; 8(1):319. PubMed ID: 28831036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention.
    Hanley GE; McAlpine JN; Miller D; Huntsman D; Schrader KA; Blake Gilks C; Mitchell G
    BMC Cancer; 2018 Mar; 18(1):254. PubMed ID: 29506471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of BRCA1 and BRCA2 pathogenic sequence variants in ovarian cancer patients in the Gulf region: the PREDICT study.
    Azribi F; Abdou E; Dawoud E; Ashour M; Kamal A; Al Sayed M; Burney I
    BMC Cancer; 2021 Dec; 21(1):1350. PubMed ID: 34930165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coming into focus: the nonovarian origins of ovarian cancer.
    Dubeau L; Drapkin R
    Ann Oncol; 2013 Nov; 24 Suppl 8(Suppl 8):viii28-viii35. PubMed ID: 24131966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRCA-associated ovarian cancer: from molecular genetics to risk management.
    Girolimetti G; Perrone AM; Santini D; Barbieri E; Guerra F; Ferrari S; Zamagni C; De Iaco P; Gasparre G; Turchetti D
    Biomed Res Int; 2014; 2014():787143. PubMed ID: 25136623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Family history and BRCA1/BRCA2 status among Japanese ovarian cancer patients and occult cancer in a BRCA1 mutant case.
    Hirasawa A; Masuda K; Akahane T; Ueki A; Yokota M; Tsuruta T; Nomura H; Kataoka F; Tominaga E; Banno K; Makita K; Susumu N; Sugano K; Kosaki K; Kameyama K; Aoki D
    Jpn J Clin Oncol; 2014 Jan; 44(1):49-56. PubMed ID: 24218521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Dominantly Inherited 5' UTR Variant Causing Methylation-Associated Silencing of BRCA1 as a Cause of Breast and Ovarian Cancer.
    Evans DGR; van Veen EM; Byers HJ; Wallace AJ; Ellingford JM; Beaman G; Santoyo-Lopez J; Aitman TJ; Eccles DM; Lalloo FI; Smith MJ; Newman WG
    Am J Hum Genet; 2018 Aug; 103(2):213-220. PubMed ID: 30075112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic and epigenetic profiling of BRCA1/2 in ovarian tumors reveals additive diagnostic yield and evidence of a genomic BRCA1/2 DNA methylation signature.
    Aref-Eshghi E; McGee JD; Pedro VP; Kerkhof J; Stuart A; Ainsworth PJ; Lin H; Volodarsky M; McLachlin CM; Sadikovic B
    J Hum Genet; 2020 Oct; 65(10):865-873. PubMed ID: 32483276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No Association of Early-Onset Breast or Ovarian Cancer with Early-Onset Cancer in Relatives in
    Imbert-Bouteille M; Corsini C; Picot MC; Mizrahy L; Akouete S; Huguet H; Thomas F; Geneviève D; Taourel P; Ychou M; Galibert V; Rideau C; Baudry K; Kogut Kubiak T; Coupier I; Hobeika R; Macary Y; Toledano A; Solassol J; Maalouf A; Daures JP; Pujol P
    Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peripheral blood DNA methylation detected in the BRCA1 or BRCA2 promoter for sporadic ovarian cancer patients and controls.
    Bosviel R; Michard E; Lavediaux G; Kwiatkowski F; Bignon YJ; Bernard-Gallon DJ
    Clin Chim Acta; 2011 Jul; 412(15-16):1472-5. PubMed ID: 21557934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883).
    Hauke J; Hahnen E; Schneider S; Reuss A; Richters L; Kommoss S; Heimbach A; Marmé F; Schmidt S; Prieske K; Gevensleben H; Burges A; Borde J; De Gregorio N; Nürnberg P; El-Balat A; Thiele H; Hilpert F; Altmüller J; Meier W; Dietrich D; Kimmig R; Schoemig-Markiefka B; Kast K; Braicu E; Baumann K; Jackisch C; Park-Simon TW; Ernst C; Hanker L; Pfisterer J; Schnelzer A; du Bois A; Schmutzler RK; Harter P
    J Med Genet; 2019 Sep; 56(9):574-580. PubMed ID: 30979843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Germline mutations in Black patients with ovarian, fallopian tube and primary peritoneal carcinomas.
    Somasegar S; Weiss AS; Norquist BM; Khasnavis N; Radke M; Manhardt E; Pennil C; Pennington KP; Eckert MA; Chryplewicz A; Lengyel E; Swisher EM
    Gynecol Oncol; 2021 Oct; 163(1):130-133. PubMed ID: 34452747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study.
    de Juan I; Palanca S; Domenech A; Feliubadaló L; Segura Á; Osorio A; Chirivella I; de la Hoya M; Sánchez AB; Infante M; Tena I; Díez O; Garcia-Casado Z; Vega A; Teulé À; Barroso A; Pérez P; Durán M; Carrasco E; Juan-Fita MJ; Murria R; Llop M; Barragan E; Izquierdo Á; Benítez J; Caldés T; Salas D; Bolufer P
    Fam Cancer; 2015 Dec; 14(4):505-13. PubMed ID: 26026974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.